|  |  |
| --- | --- |
| ICMJE DISCLOSURE FORM | |
| **Date:** | 1/29/2024 |
| **Your Name:** | Guilherme Pessoa-Amorim |
| **Manuscript Title:** | Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England |
| **Manuscript Number (if known):** | Click or tap here to enter text. |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. | |

|  | | | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
| --- | --- | --- | --- | --- |
| **Time frame: Since the initial planning of the work** | | | | |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  **No time limit for this item.** | | |  |  | | --- | --- | |  | **None** | | |
| **Time frame: past 36 months** | | | | |
| **2** | | Grants or contracts from any entity (if not indicated in item #1 above). | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | | UK Research and Innovation, NIHR, Wellcome Trust (through the COVID-19 Therapeutics Accelerator), the Oxford BHF Centre of Research Excellence, and Health Data Research UK | Research grant to the University of Oxford to support the RECOVERY trial | | NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections and NIHR Clinical Trials Unit Support Funding | Core funding to the University of Oxford | | Medical Research Council Population Health Research Unit | PhD funding to Guilherme Pessoa-Amorim and Mark Campbell | | MRC Network of Hubs for Trials Methodology Research | PhD funding to Charlie Harper | | Novartis | Marion Mafham and Martin Landray are applicants in a research grant to the University of Oxford, unrelated to this work | | Novo Nordisk | Marion Mafham is an applicant in a research grant to the University of Oxford, unrelated to this work | | Boehringer Ingelheim | Martin Landray is an applicant in a research grant to the University of Oxford, unrelated to this work | | Regeneron, Sanofi, Moderna, FluLab, Google Ventures and Schmidt Futures | Martin Landray is an applicant in grants to Protas from Regeneron, Sanofi, Moderna, FluLab, Google Ventures and Schmidt Futures (all unrelated to this work). | | |
| **3** | | Royalties or licenses | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **4** | | Consulting fees | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | |  |  | | |
| **5** | | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **6** | | Payment for expert testimony | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **7** | | Support for attending meetings and/or travel | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **8** | | Patents planned, issued or pending | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **9** | | Participation on a Data Safety Monitoring Board or Advisory Board | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **10** | | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **11** | | Stock or stock options | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
| **12** | | Receipt of equipment, materials, drugs, medical writing, gifts or other services | |  |  | | --- | --- | |  | **None** |  |  |  |  |  | | --- | --- | --- | --- | | Roche, AbbVie, Regeneron, GSK | Provided study drugs for evaluation in the RECOVERY trial |  |  | | |
| **13** | | Other financial or non-financial interests | |  |  | | --- | --- | |  | **None** |  |  |  | | --- | --- | |  |  | |  |  | |  |  | | |
|  | |  |  | |
| **Please place an “X” next to the following statement to indicate your agreement:** | | | | |
|  | | I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | |